Adimmune (TPE:4142) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:4142 Adimmune Corp TPE:4142
59 GF Score
Price NT$17.15
GF Value NT$24.02
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Adimmune Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

TPE:4142
59GF Score
Adimmune Corp TPE:4142
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Adimmune (TPE:4142) Overvalued in 2026?

Based on GuruFocus' analysis, Adimmune stock appears to be undervalued. The current stock price of NT$17.15 is trading 28.6% below its estimated GF Value™ of NT$24.02. GuruFocus considers Adimmune to be Modestly Undervalued.

Key valuation signals for TPE:4142:

  • Total Noninterest Expense:
  • GF Value™: NT$24.02 vs. price of NT$17.15 (28.6% below fair value)
  • GF Score™: 59/100 with 6 warning signs

No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adimmune Business Description

Address Tanxing Road, No. 3, Section 1, Tanzi District, Taichung City, TWN, 427003
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
59GF Score

Get the complete analysis for TPE:4142

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.15
Price
NT$24.02
GF Value